Recruiting

Gepotidacin

Sponsor:

GlaxoSmithKline

Code:

NCT07850141

Conditions

Sexually Transmitted Diseases

Eligibility Criteria

Sex: Female

Age: 15 - 50

Healthy Volunteers: Not accepted

Interventions

None (Observational study)

None (Observational study)

Study Details

Brief summary:

The purpose of this study is to monitor pregnancies exposed to gepotidacin and to evaluate possible teratogenic effects or birthweight-lowering effects of this medication relative to the primary outcomes of major congenital malformations (MCMs) and small for gestational age (SGA), as well as to evaluate secondary maternal, fetal, and infant outcomes.

Conditions

Sexually Transmitted Diseases

Study ID

NCT07850141

Start date

Sep 30, 2026

Status verified date

Nov, 2026

Completion date

Aug 19, 2032

Anticipated

Primary completion date

Aug 19, 2032

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 15 - 50

Healthy Volunteers: Not accepted

Inclusion Criteria:

For Both cohorts:

  • Participants with aged 15 to 50 years
  • United States resident
  • Currently pregnant
  • Participants personally signed and dated informed consent document or, upon waiver of written consent by the relevant Institutional review board (IRB), verbal consent indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study
  • Authorization and contact information for the reporter (e.g., participant, maternal/infant Health care provider (HCP), prescriber) to allow for follow-up

Exposed cohort:

• Exposed to gepotidacin at any time during pregnancy or the relevant exposure window

Comparator cohort:

  • Diagnosis of and treatment for uUTI at any time during pregnancy or the relevant comparator product exposure window
  • Exposed to one or more American College of Obstetricians and Gynecologists (ACOG)-recommended treatments for acute cystitis at any time during pregnancy or the relevant comparator product exposure window

Exclusion Criteria:

For Both cohorts:

• Diagnosis of known MCMs for the index pregnancy prior to enrollment

Exposed cohort:

• None

Comparator cohort:

• Exposure to gepotidacin at the time of enrollment

Study Design

Enrollment

614 participants

Anticipated

Interventions and Outcome Measures

Arms

Exposed cohort

Pregnant participants with uncomplicated urinary tract infection (uUTI) who are exposed to gepotidacin during the relevant exposure window

Comparator cohort

Pregnant participants with uncomplicated urinary tract infection (uUTI) who are exposed to standard-of-care antibiotics during the relevant exposure window

Interventions

None (Observational study)

Not Applicable since Observational Study

None (Observational study)

Not Applicable since Observational Study

Primary outcome measure

  • Number of infants with major congenital malformations (MCMs) [ Time Frame: At pregnancy outcome, with follow-up through 12 months after delivery ]
  • Number of infants with small-for-gestational-age births (SGA) [ Time Frame: At live birth ]

Central Contacts and Locations

Central contacts

US GSK Clinical Trials Call Center

877-379-3718GSKClinicalSupportHD@gsk.com

Locations

PPD / Thermofisher

Recruiting

Wilmington, North Carolina, United States, 28401

Contacts

More Information

Sponsor

GlaxoSmithKline

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Keywords

  • Observational
  • Cohort
  • Gepotidacin
  • Urinary tract infections
  • Neonatal
  • Maternal
  • Pregnancy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.